Michael Gehr, of Edmond, and his family are on a mission to help find a cure for a rare genetic disease that he was diagnosed ...

In this video, Khalaf Bushara, MD, FRCP, highlights the greatest challenges in Friedreich's ataxia care and management.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...

GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival ...

It’s been years since the Cannes Lions International Festival of Creativity awarded its top prize to a traditional ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.